Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births

SERA PROGNOSTICS, INC.

2026-Q1 EPS reported -$0.17 revenue$14,000

Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
PRIME trial (5,018 women) showed PreTRM test cut early preterm births 56% (<32 wks) and 32% (<35 wks); NICU admissions down 20%.
Cash and securities $86.8M; cash runway extended through 2029 via cost restructuring.
Launched third physician partnership; active payer discussions with 13 payers across 15 states.
CE marking submission for Europe on track for mid-2026; expanding European evidence base.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

SERA PROGNOSTICS, INC. reported the first quarter ended March 31, 2026 results: revenue $14,000, net income $8.4 million.

Period: the first quarter ended March 31, 2026
Revenue: $14,000
Net income: $8.4 million
Result: reported results

Exact text from the filing

First quarter 2026 revenue was $14,000 compared to $38,000 for the first quarter of 2025.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SERA PROGNOSTICS, INC. filing history →

Source: SEC EDGAR

accession 0001534969-26-000024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.